Mumbai's TruNativ, the clean-label nutrition brand, just raised $30 million in Series B funding. OrbiMed, a global firm known for biotech and pharma bets, led the round, signaling a deeper play into India's consumer health D2C space. This capital will fuel an aggressive push into channels tackling prevalent issues like sugar overconsumption and protein deficiency.
How We Got Here
Founded in 2019 by the Malhotra mother-son duo, TruNativ has spent five years building out its clean-label nutrition platform. They claim majority market share in quick-commerce sugar replacement and hold the #1 rank for dietary fibre and sweeteners on Amazon India.
The Numbers
- The Series B included a mix of primary investment and secondary transactions, allowing early investors an exit.
- TruNativ plans to use the $30 million to aggressively expand its distribution across D2C, quick commerce, modern trade, and pharmacy channels.
- A portion of the capital also targets growth for its B2B2C ingredient business, a less visible but strategic play.
- The brand's portfolio spans five specific nutrition categories: sugar substitution, protein, gut health, beauty wellness, and performance.
What Happens Next
🇮🇳 Why This Matters for India
For D2C founders in Bangalore and Pune targeting consumer health, this OrbiMed cheque validates the clean-label trend and the scale potential beyond just metro-centric niches.
The Take
The real win here is for "clean-label" as a category: OrbiMed's $30M stamp signals deep institutional belief in consumer demand for verifiable ingredients. Expect to see traditional FMCG players scramble to acquire or launch similar portfolios within the next 12 months.
Source:
YourStory ↗